Introduction
============

Red blood cell distribution width (RDW) is a conventional biomarker for erythrocyte volume variability and an indicator of erythrocyte homeostasis [@B1]. Recent evidence shows that anisocytosis is involved in a variety of human diseases such as cardiovascular diseases [@B2],[@B3], thrombosis [@B3], diabetes [@B4], and cancers [@B5],[@B6]. High RDW level is a negative prognoistic marker for these diseases, and inflammation is the leading mechanism [@B1].

Inflammation is a key regulator of cancer initiation and progression [@B7]. Recently, RDW, which plays a critical role in inflammatory response, has attracted attention because of the connection between inflammation and cancer. RDW increases in malignant tumors [@B8],[@B9]. Furthermore, higher RDW levels are also significantly associated with advanced stages of cancer and metastasis [@B10],[@B9].

A mounting body of evidence suggests that elevated RDW level also correlated with poor prognosis for various cancers, which included esophageal cancer [@B11]-[@B15], gastrointestinal tumors [@B16]-[@B18], HCC [@B19]-[@B22], lung cancer [@B23]-[@B26], and hematological malignancies [@B27]-[@B30]. However, the prognostic impact of RDW has not been comprehensively investigated because of the inevitable heterogeneity of the samples studied. The aim of the present study was to assess the relationship between RDW and clinical outcomes in patients with cancer.

Methods
=======

Search strategy
---------------

Our meta-analysis was registered in PROSPERO with the number CRD42018093419. Studies were identified from MEDLINE and EMBASE up to April 2018. Medical subject headings and Emtree headings were searched and combined with the following key-words: "red blood cell distribution width OR RDW" and "prognosis OR prognostic OR survival OR outcome" and "cancer OR tumor OR carcinoma OR neoplasm". The references of the included articles were also scanned to identify additional studies. Supplementary Table [1](#SM0){ref-type="supplementary-material"} presents the full search strategy.

Study selection
---------------

We included prospective or retrospective studies that assessed RDW level prior to any treatment in patients with proven pathological diagnosis of cancer. Furthermore, eligible studies should provide hazard ratio (HR) with a 95% confidence interval (CI) for clinical outcomes, or enough data to calculate these quantities. We excluded studies based on the time when blood samples were collected; studies were eliminated if they involved patients who received any therapy within two weeks prior to blood donation. Conference abstracts, review articles, case reports, letter, animal studies, or in vitro studies were not eligible for our analysis. Studies with duplicate or overlapping data were also excluded. Two reviewers (PF-W and SY-S) independently performed the study selection and resolved any disagreements via discussion.

Data extraction
---------------

Data from all included studies were extracted by one author (SY-S) and was cross-checked by another author (PF-W). Data were extracted using the name of the first author, year of publication, country, tumor type, clinical/pathological tumor stage, study characteristics (sample size, age, and gender), stage criteria, statistical methods used to calculate the cut-off value for RDW, survival outcomes, and sources of HRs (univariate or multivariate). Furthermore, we calculated the male-to-female gender ratio (M/F gender ratio) to precisely assess the various gender distributions among the included cohorts. The interval of the M/F gender ratio of a balanced composition ranged from one to two; the M/F ratio of a female-dominant composition was less than one, whereas that of male-dominant cohorts was more than two. HRs and 95% CIs were extracted for overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS). We used the Engauge digitizer to estimate HRs and their 95% CIs if eligible studies provided only Kaplan-Meier curves and we received no response from the investigators after two requests for HRs [@B31]. All disagreements were resolved by consensus.

Outcomes
--------

We defined OS as the time from the study enrollment to the date of death from any cause or last follow-up. As DFS, PFS, and RFS share similar endpoints, they were analyzed together as one outcome, DFS/PFS/RFS [@B32]-[@B34].

Statistical analyses
--------------------

We used STATA version 14.0 (STATA, College Station, TX) in all analyses. Multivariate-adjusted HRs were used when possible, and univariate HRs were included in the meta-analysis if multivariate-adjusted HRs were missing. Pooled estimates with 95% CIs, separately for studies providing OS and DFS/PFS/RFS, were derived using the Mantel-Haenszel method. Further analyses for exploring heterogeneity were comprehensively conducted through subgroup analysis, sensitivity analyses, and meta-regression. Heterogeneity was assessed using the χ^2^ test and expressed as the I^2^ index (25% = low, 50% = medium, 75% = high) [@B35]. A random effects model was used when heterogeneity was \> 50%. Alternatively, a fixed effects model was conducted for the meta-analysis. Publication bias was assessed by visual inspection of funnel plots, combined with Egger\'s test or Begg\'s test [@B36],[@B37]. Additionally, we applied Duval and Tweede\'s trim and fill method to estimate corrected effect size after adjustment for publication bias [@B38]. A set of modified predefined criteria was utilized to evaluate the risk of bias in eligible studies [@B39]-[@B41]. P-values \< 0.05 were considered statistically significant.

Results
=======

Study characteristics
---------------------

Our literature search identified 401 potentially relevant records. Eighty-nine articles were further removed due to duplication. Two-hundred and fifteen studies with irrelevant content were excluded after screening titles and abstracts. Ninety-seven articles were reviewed with full texts. In total, forty-nine studies consisting of 19,790 patients were finally included in our analysis according to the inclusion and exclusion criteria (Fig. [1](#F1){ref-type="fig"}) [@B42]-[@B47],[@B23],[@B48],[@B11],[@B49],[@B27],[@B28],[@B19],[@B50]-[@B52],[@B12],[@B53],[@B24],[@B54],[@B25],[@B55],[@B29],[@B13],[@B26],[@B14],[@B15],[@B20],[@B10],[@B21],[@B56],[@B16],[@B57]-[@B62],[@B30],[@B63]-[@B66],[@B22],[@B67],[@B17],[@B68],[@B18],[@B69].

The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. OS and DFS/PFS/RFS were reported in 45 and 26 articles, respectively. Sixteen different solid cancer types and five different hematological malignancies were investigated in the eligible studies. For solid tumors, the most frequently evaluated cancer was upper gastrointestinal cancer (UGI) (including patients with pancreatic, esophageal, and gastric cancer) (n = 8), followed by hepatic cancer (HCC) (n = 4), non-small cell lung cancer (NSCLC) (n = 4), colorectal cancer (CRC) (n = 3), breast cancer (n = 3), and glioma (n = 3). Multiple myeloma (MM) (n = 5) and diffuse large B-cell lymphoma (DLBCL) (n = 2) were the most-studied diseases among hematological malignancies. A large number of studies (90%) enrolled patients with mixed-stage, whereas only a few studies specifically investigated patients with early- (10%) and advanced-stage (12%) disease. Five different methods for defining cut-off values were observed in the included studies. Region under the curve (ROC) analysis was used most frequently (n = 23), followed by the upper limit of reference range (n = 12) and empirical values based on previous studies (n = 6). With respect to cut-off values, most studies (94%) selected coefficient of variation (CV) to evaluate RDW, whereas others used standard deviation (SD). The cut-off values ranged from 12.20% to 20.00%. However, thirty-six studies (80%) applied cut-off values in the range of 13-15%. Furthermore, we evaluated the demographic characteristics among the cohorts, such as age, gender, and country of origin. Twenty-two studies (52%) enrolled elderly population, the median or mean age of whom was \> 60 years. The number of cohorts with balanced gender composition (n = 22) was nearly equal to that of cohorts with female or male dominant composition (n = 24). Sixty-three percent cohorts were originally from Asian countries, whereas the others were from Western countries. In our assessment of study quality, nine studies had quality scores ≤ 7, and the remaining 40 studies had scores \> 7 (Supplementary Table [3](#SM0){ref-type="supplementary-material"}).

Overall survival
----------------

Forty-five studies with 18,767 patients were analyzed for OS. The pooled HRs of higher pretreatment RDW level was 1.508 (95% CI = 1.387-1.639; Fig. [2](#F2){ref-type="fig"}). Next, we performed comprehensive analysis to explore the high heterogeneity, including subgroup analyses, sensitivity analysis, and meta-regression.

Table [2](#T2){ref-type="table"} shows the subgroup analysis of the included studies, based on eight factors, including tumor type, tumor stage, age, gender distribution, country of origin, cut-off value, method of defining the cut-off value, and HR calculation. In solid tumors, CRC had the strongest relationship with poor OS (HR = 1.932; 95% CI = 1.397-2.673), followed by HCC (HR = 1.430; 95% CI = 1.232-1.660) and NSCLC (HR = 1.440; 95% CI = 1.103-1.880). However, UGI cancer and breast cancer with elevated RDW were not associated with worse OS (UGI cancer: HR = 1.091; 95% CI = 0.925-1.286. Breast cancer: HR = 2.092, 95% CI = 0.833-5-255). For hematological malignancies, negative OS outcomes were observed in MM and DLBCL (MM: HR = 1.692; 95% CI = 1.256-2.281. DLBCL: HR = 3.178, 95% CI = 1.853-5.450). In addition, patients in either early or advanced stage showed adverse relationship between increased pretreatment RDW and poor OS. Furthermore, combined HR remained significant in subgroups stratified by demographic factors, including age, gender, and country of origin. Studies with cut-off values between 13% and 14% had worse HR than others. However, considerable variety was present in the methodologies used for defining cut-off values. ROC analysis was the most widely used method and had relatively closer relationship with poorer HRs. Finally, studies using univariate (HR = 1.525; 95% CI = 1.380-1.686) and multivariate analyses (HR = 1.477; 95% CI = 1.342-1.626) showed that higher RDW levels were associated worse OS.

In sensitivity analysis under "one study removed" model, the pooled HRs for OS were significantly affected by exclusion of Wang et al. (Supplementary Table [4](#SM0){ref-type="supplementary-material"}). In addition, meta-regression did not demonstrate any potential source of heterogeneity (Supplementary Table [5](#SM0){ref-type="supplementary-material"}).

DFS/PFS/RFS
-----------

Twenty-six studies with 7,350 patients provided HRs and 95% CIs for DFS/PFS/RFS. Overall, elevated pretreatment RDW level were associated with worse DFS/PFS/RFS (HR = 1.576; 95% CI = 1.447-1.716; Fig. [3](#F3){ref-type="fig"}). Subgroup analyses were performed by stratification based on tumor type, tumor stage, age, gender distribution, country of origin, cut-off value, method of defining the cut-off value, and HR calculation (Supplementary Table [2](#SM0){ref-type="supplementary-material"}). Higher levels of RDW were associated with shorter DFS/PFS/RFS in patients with HCC (HR = 2.104, 95% CI = 1.577-2.807), CRC (HR = 1.636; 95% CI = 1.211-2.211), and hematological malignancies (HR = 2.077; 95% CI = 1.644-2.625).

Overall, HRs remained significant in subgroups stratified by demographic factors, including age, gender, and country of origin. Furthermore, associations between higher RDW levels and worse DFS/PFS/RFS were also observed with cut-off values \> 13% and \< 14% (HR = 1.818; 95% CI = 1.474-2.243). Studies which utilized ROC analysis to define cut-off values showed comparatively worse HRs (HR = 1.770; 95% CI = 1.536-2.040). Finally, both univariate and multivariate analyses for HR calculation indicated poor DFS/PFS/RFS outcomes.

Publication bias
----------------

We observed evidence of publication bias in studies provided on OS (n = 45) and DFS/PFS/RFS (n = 26) by visual inspection of the funnel plot (Supplementary Fig. [1](#SM0){ref-type="supplementary-material"}), which was further confirmed by Egger\'s tests (P \< 0.001) (Supplementary Fig. [2](#SM0){ref-type="supplementary-material"}). The trim and fill method was applied to address these problems. Intriguingly, pooled adjusted HRs of OS and DFS/PFS/RFS subsets were consistent with our primary analysis (Supplementary Table [6](#SM0){ref-type="supplementary-material"} and Supplementary Fig. [3](#SM0){ref-type="supplementary-material"}).

Discussion
==========

RDW is an easily acquired, non-invasive, and inexpensive maker, which can be used routinely for clinical purpose. This is the first meta-analysis to comprehensively evaluate the prognostic role of RDW in cancers. High RDW level was correlated with unfavorable clinical outcomes in most tumor types and stages. The prognostic value of RDW was also independent of patient age, gender, or region.

Gradual increase in RDW with age has been reported in healthy people [@B1]. However, association between gender and RDW is still unclear. Certain studies indicated that RDW was slightly higher in females [@B70],[@B71], whereas others observed no significant gender-based difference in RDW values [@B72],[@B73]. Hence, an age- and gender-stratified subgroup analysis was performed. Poor survival outcome was associated with higher RDW in elder or younger patients with cancer. Similarly, both females and males with high RDW levels exhibited poor survival. These results showed that RDW can predict survival independent of age and gender. The cut-off value of 14.6% is conventionally used for anemia [@B74]. However, the lack of unified RDW cutoff values for cancer survival prediction was a matter of concern [@B73].

Majority of the studies used ROC analysis to define cut-off values, which ranged from 12.20% to 20.00%. However, 36 studies (80%) applied cut-off values between 13% and 15%. We observed that cut-off values defined by ROC curves were more likely to predict poor clinical outcomes. Furthermore, subgroups with cut-off values between 13% and 14% were mostly negatively associated with poor OS and DFS/PFS/RFS. We conclude that more studies are required to determine uniform cut-off values in specific cancer types.

The mechanisms underlying the prognostic impact of RDW on cancers were due to inflammation [@B75], poor nutritional status [@B76], and oxidative stress [@B77]. First, it is well-known that malignant tumors are accompanied by systemic inflammatory response [@B76]. RDW was identified as an inflammatory marker in patients with cancer due to its positive association with widely used plasma inflammatory biomarkers such as C-reactive protein (CRP) [@B43],[@B28],[@B14], erythrocyte sedimentation rate (ESR) [@B60],[@B47], and interleukin (IL)-6 [@B78] levels. Elevated RDW level reflected the presence of immature juvenile red blood cells in the periphery. Various cytokines affect erythropoiesis via erythropoietin (EPO) production, inhibition of erythroid progenitors, and reduction in iron release. Previous *in vitro and in vivo* studies have demonstrated that EPO production was inhibited by inflammatory cytokines [@B79]-[@B81] such as IL-6, interferon-gamma (IFN-γ), IL-1β, and tumor necrosis factor-alpha (TNF-α). In addition, IL-1α and IL-1β play important roles in suppression of erythroid progenitors [@B82]. Hepcidin, a regulator of iron metabolism, is increasingly expressed when plasma IL-6 level is elevated [@B83],[@B84], which results in iron deficiency and anemia [@B80]. In sum, it is plausible to hypothesize that RDW can reflect inflammatory status in cancer. Second, malnutrition is another hallmark of cancer because of reduction in appetite and weight. This results in deficiency of various minerals and vitamins such as iron, folate and vitamin B12, which consequently contribute to the increase in RDW [@B85],[@B42]. Numerous studies have also shown that low albumin level is associated with increased RDW level in cancer patients [@B24],[@B60],[@B30],[@B69], which also indicated the relationship between high RDW level and poor nutritional status in patients with cancer. Third, oxidative stress was recognized as a negative factor leading to significant variation in erythrocyte size. Free reactive oxygen species (ROS) can damage protein, lipids, and DNA, which may reduce RBC survival [@B86]. Taken together, high RDW level is well-suited to reflect both chronic ongoing inflammation and poor nutritional status in patients with cancer.

Among solid tumors, CRC and HCC showed relatively strong association between RDW level and negative prognosis. This significant association in CRC may be attributed to chronic inflammatory status and cancer-associated anemia. CRC can develop from inflammatory bowel diseases and inflamed polyps [@B87]-[@B89]. Thus, inflammation plays a crucial role in colorectal carcinogenesis [@B90]. In addition, chronic blood loss is a common symptom of CRC, which can lead to iron deficiency, anemia, and subsequent rise in RDW values. HCC is one of the most important inflammation-associated cancers [@B91]; it is closely associated with chronic inflammation and fibrosis, which is known as hepatic inflammation-fibrosis-cancer (IFC) axis. IL-6 and TNF-α expression was elevated and erythrocyte maturation was suppressed in patients with HCC [@B92]. Furthermore, within the diseased liver, free radicals such as ROS and nitrogen species (NO) were generated by the cells of the hepatic immune system, including recruited neutrophils, monocytes, and Kupffer Cells [@B92]. In sum, elevated RDW was negatively associated with the prognosis of certain cancer types, which encompassed multiple pathways affecting erythropoiesis.

In our meta-analysis, pretreatment RDW was identified as a robust predictor of cancer prognosis. However, there are several limitations. First, there was considerable heterogeneity when HRs for OS outcomes were pooled. However, subgroup analysis showed that various methodologies for defining cut-off values may be a major cause of heterogeneity. The robustness of our results was further confirmed by sensitivity analysis and meta-regression, which did not significantly alter the pooled effect size for OS. Second, we observed that some studies evaluated the relationship between delta RDW level [@B17],[@B27],[@B16] or delta MCV level [@B93]-[@B96] and cancer prognosis after the patients had undergone certain therapies. However, we focused on the prognostic role of absolute value of pretreatment RDW level in this analysis as delta RDW level may be dependent on many cofactors such as therapies and types of cancer. Finally, although pretreatment RDW level can reflect both inflammatory and nutritional status, it would be more convincible if combined with other potential predictors, such as neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI). More studies are required for building a new prognostic and comprehensive model for predicting survival outcomes in patients with cancer.

Conclusions
===========

Pretreatment RDW level is a potential predictor of cancer prognosis, independent of most tumor type and stage and patient age and gender. Optimal RDW cut-off values can be defined by ROC analysis. Cut-off values between 13% and 14% were negatively associated with poor survival outcomes. Uniform cut-off values for specific cancer types are required for further evaluation in future.
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###### 

Main characteristics of 49 eligible studies included in the meta-analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, Year     Country               Tumor type                                              Study design    Stage                                             Criteria            Sample size   Age^a^                                                     Gender (Female/male)                               Definition of cut-offs                   Cut-offs value                Outcome measures   HRs source   variables
  --------------- --------------------- ------------------------------------------------------- --------------- ------------------------------------------------- ------------------- ------------- ---------------------------------------------------------- -------------------------------------------------- ---------------------------------------- ----------------------------- ------------------ ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Perlstein\      USA                   NR                                                      prospective     NR                                                NR                  NR            NR                                                         NR                                                 4th quartile                             14.35%                        OS                 UV           
  et al 2009                                                                                                                                                                                                                                                                                                                                                                                                             

  Koma\           Japan                 Lung cancer                                             retrospective   I-IV                                              UICC-7              332           71.5 (38-94)                                               109/223                                            Upper limit                              15.00%                        OS                 UV; MV       RDW; Stage; ECOG PS; Other diseases; Treatment; Albumin; CRP
  et al 2013                                                                                                                                                                                                                                                                                                                                                                                                             

  Abakay\         Turkey                Malignant mesothelioma                                  retrospective   NR                                                NR                  152           58.2 ± 11.9                                                65/90                                              Arbitrary^c^                             20.00%                        OS                 MV           RDW; Histopathological subtype; NLR
  et al 2014                                                                                                                                                                                                                                                                                                                                                                                                             

  Lee\            Korea                 MM                                                      retrospective   I-III                                             ISS                 146           61 (32-83)                                                 55/91                                              Upper limit                              14.50%                        OS; PFS            UV; MV       RDW; Age at diagnosis; ECOG; Cytogenetic risk; B2MG; Albumin; LDH; Hemoglobin; Calcium; Induction with novel agents; ASCT
  et al 2014                                                                                                                                                                                                                                                                                                                                                                                                             

  Riedl\          Austria               Multiple malignancies^b^                                prospective     Localized; Distant metastasis; Not classifiable   NR                  1840          62 (52-68)                                                 843/997                                            Upper limit; 4th quartile                16%; 14.6%                    OS                 UV; MV       RDW; Age; Sex
  et al 2014                                                                                                                                                                                                                                                                                                                                                                                                             

  Wang\           China                 RCC                                                     retrospective   I-IV                                              AJCC-7              316           56.83 ± 11.68                                              108/210                                            ROC                                      12.85%                        OS                 MV           RDW; Smoking; Hemoglobin; MCV; Platelet; WBC; Albumin; ESR
  et al 2014                                                                                                                                                                                                                                                                                                                                                                                                             

  Warwick\        UK                    NSCLC                                                   retrospective   T1-3; N0-1                                        AJCC-7              917           67.21 (17-90)                                              440/477                                            4th quartile                             15.30%                        OS                 MV           RDW; Age; Alcohol intake; Emphysema; Squamous carcinoma; predicted postoperative FEV1; T stage I; T stage III; N stage I
  et al 2014                                                                                                                                                                                                                                                                                                                                                                                                             

  Yao\            China                 Breast cancer                                           retrospective   Tis-T3;\                                          NR                  608           52.4 ± 10.8                                                608/0                                              ROC                                      13.45%                        OS                 MV           RDW; Node stage; Molecular subtype; NLR
  et al 2014                                                                                                    N0-3                                                                                                                                                                                                                                                                                                     

  Chen\           China                 ESCC                                                    retrospective   T1-4; N0-3                                        NR                  277           NR                                                         37/240                                             Mean                                     14.50%                        CSS                MV           RDW; Tumor length; Vessel invasion; Differentiation; T stage; N stage
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Cheng\          Taiwan                UTUC                                                    retrospective   Tis-T4;\                                          AJCC-6              420           68 ± 10.3                                                  116/79                                             Within central 80 % distribution.        14.00%                        OS; CSS            UV; MV       RDW; T stage; LN metastasis; Tumor grade; Adjuvant chemotherapy; WBC; NLR
  et al 2015                                                                                                    N0-+                                                                                                                                                                                                                                                                                                     

  Iriyama\        Japan                 CML                                                     retrospective   NR                                                NR                  84            51 (22-85)                                                 30/54                                              Arbitrary^c^                             15.00%                        OS; EFS            UV           
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Periša\         Croatia               DLBL                                                    retrospective   I-IV                                              Ann Arbor           81            64.0 (52.5-72.5)                                           52/29                                              ROC                                      15.00%                        OS; EFS            MV           RDW; Age; Sex; IPI; LDH; Clinical stage AA; ECOG PS
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Smirne\         Italy                 HCC                                                     retrospective   A-D                                               BCLC                314           Training cohort 70 (62-77); Validation cohort 67 (59-74)   Training cohort 52/156; Validation cohort 26/80    Upper limit                              14.60%                        OS                 MV           RDW; Age at diagnosis; BCLC stage; Child-Pugh-Turcotte score; tumor size; serum AFP
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Wang\           USA                   Breast cancer                                           retrospective   I-IV                                              AJCC-6              1816          Black 57.26 ± 13.99; White 60.05 ± 13.43                   1816/0                                             NR                                       14.50%                        OS                 MV           RDW; Age; Year of diagnosis; Ethnicity; Smoking status, Drinking status; Stage; Grade; Estrogen receptor status; progesterone receptor status
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Xie\            USA                   SCLC                                                    prospective     Extensive; Limited                                NR                  938           65.4 ± 11.0                                                438/500                                            Upper limit                              15.00%                        OS                 UV; MV       RDW; NLR; PLR; Age at diagnosis; Gender; ECOG performance status; Chest radiation; Chemotherapy; Liver metastases; Numbers of metastatic sites
  et al 2015                                                                                                                                                                                                                                                                                                                                                                                                             

  Auezova\        Kazakhstan            Gliomas                                                 retrospective   Grade I-IV                                        WHO 2007            178           41.58 ± 1.04                                               85/93                                              ROC                                      13.95%                        OS                 UV           
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Hirahara\       Japan                 ESCC                                                    retrospective   I-III                                             AJCC-7              144           NR                                                         15/129                                             Upper limit                              50fL                          CSS                UV; MV       RDW; Stage; Tumor size; Operation time
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Huang\          China                 Breast cancer                                           retrospective   I-III                                             AJCC-6              203           37 (24-40)                                                 203/0                                              ROC                                      13.75%                        OS; DFS            MV           RDW; PVI present; PR positive; Stage
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Ichinose\       Japan                 NSCLC                                                   retrospective   T1-4; N0-2                                        UICC-7              992           NR                                                         NR                                                 Median                                   13.80%                        OS; DFS            MV           RDW; Gender; T factor; N factor; Sub-lobar resection; CEA; NLR; Albumin; Smoking
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Kara\           Turkey                Laryngeal carcinoma                                     retrospective   T1-4; N0-2; M0                                    AJCC-7              103           65.01 ± 9.01                                               NR                                                 ROC                                      14.05%                        OS                 MV           RDW; Tumor stage
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Kos\            Turkey                NSCLC                                                   retrospective   I-IV                                              UICC-7              146           56.5 (26-83)                                               15/131                                             Median; ROC; Upper limit; Arbitrary^c^   14%; 14.2%; 14.5%;\           OS                 UV           
  et al 2016                                                                                                                                                                                                                                                                                                                                               15%                                                           

  Liang\          China                 Glioblastoma                                            retrospective   NR                                                NR                  109           54 (19-85)                                                 42/67                                              ROC                                      14.10%                        OS                 MV           RDW; Age; Tumor location; Extent of resection; Adjuvant radio/chemotherapy; MCV; MCHC
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Podhorecka\     Poland                CLL                                                     retrospective   0-IV                                              Rai                 66            63 (38-85)                                                 25/38                                              Upper limit                              14.50%                        OS                 UV           
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Sun\            China                 ESCC                                                    retrospective   I-III                                             AJCC-6              362           Median 58; Mean 57.96                                      94/268                                             ROC                                      13.60%                        OS; DFS            UV           
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Uysal\          Turkey                NSCLC                                                   retrospective   IA-IIIA                                           NR                  249           60.8 ± 9.1                                                 41/208                                             Upper limit                              14.60%                        OS; DFS            UV           
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Wan\            China                 ESCC                                                    retrospective   I-III                                             AJCC/\              179           63.0 (42-77)                                               29/150                                             Upper limit                              15.00%                        OS; DFS            MV           RDW; Stage (III vs. I&II); Node metastasis status; Tumor length; WBC; Albumin; CRP; NLR
  et al 2016                                                                                                                                                      UICC-7                                                                                                                                                                                                                                                 

  Zhang\          China                 ESCC                                                    retrospective   I-III                                             AJCC-7              468           59.5 ± 9.0;\                                               92/376                                             ROC                                      12.20%                        OS; DFS            MV           RDW; Age; N metastasis; Adjuvant radio/chemotherapy; Smoking; Maximum tumor diameter; MCV; CA19-9; NLR; PLR; COP-MPV
  et al 2016                                                                                                                                                                                        60 (36-81)                                                                                                                                                                                                           

  Zhao\           China                 HCC                                                     retrospective   I-IV                                              NR                  106           52 (22-75)                                                 13/93                                              Upper limit                              14.50%                        OS; DFS            MV; UV       RDW; TNM stage; Tumor size; Tumor number; Vascular invasion
  et al 2016                                                                                                                                                                                                                                                                                                                                                                                                             

  Cheng\          China                 GC                                                      retrospective   I-IV                                              AJCC-7              227           NR                                                         51/176                                             Median                                   13.00%                        OS; DFS            UV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Howell\         Japan, Italy and UK   HCC                                                     prospective     A-D                                               BCLC; CLIP scores   442           69.92 ± 10.06                                              96/346                                             NR                                       NR                            OS                 MV           Treatment-naïve HCC; NLR; CLIP score; Diarrhea on sorafenib; RDW
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Hu\             China                 ESCC                                                    retrospective   I-III                                             AJCC/\              2396          Male 55.98 ± 9.81; Female 57.93 ± 9.41                     574/1822                                           NR                                       NR                            OS                 MV           Age, body mass index, smoking, drinking, family history of cancer, systolic blood pressure, fasting blood glucose, TNM stage, tumor embolus and tumor size
  et al 2017                                                                                                                                                      UICC-7                                                                                                                                                                                                                                                 

  Kust\           Croatia               CRC                                                     retrospective   I-IV                                              AJCC-7              90            66.8 ± 9.7                                                 37/53                                              ROC                                      14.00%                        OS                 MV           RDW; Age; Gender; AJCC stage; NLR
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Li B\           China                 Hilar cholangiocarcinoma                                retrospective   I-IV                                              AJCC-7              292           60 (20-78)                                                 131/161                                            ROC                                      14.95%                        OS                 MV           RDW; Histologic grade; T stage; N stage; AJCC stage; Portal vein invasion; Hepatic artery invasion
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Li Z\           USA                   Epithelial ovarian cancer                               retrospective   I-IV                                              NR                  654           63 (28-93)                                                 654/0                                              ROC                                      14.15%                        OS                 MV           RDW; NLR; PLR; MLR; Combined RDW+NLR; Stage; Origin of cancer; Age; Histology; Grade; Residual disease
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Luo\            China                 Nasal-type, extranodal natural killer/T-cell lymphoma   retrospective   I-IV                                              Ann Arbor           191           44 (15-86)                                                 57/134                                             ROC                                      46.2 fL                       OS; PFS            MV           RDW; Local invasiveness; Hemoglobin
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Meng\           China                 MM                                                      retrospective   I-III                                             DSS                 166           61.6 ± 10.8                                                78/88                                              Arbitrary^c^                             14.00%                        OS; PFS            UV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Sun\            China                 Prostate cancer                                         retrospective   NR                                                NR                  171           68.5 ± 8.4                                                 0/171                                              ROC                                      12.90%                        OS                 UV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Tangthongkum\   Thailand              Oral cancer                                             retrospective   I-IV                                              AJCC-7              374           60 (21-92)                                                 133/241                                            Arbitrary^c^                             14.05%                        OS; DFS; RFS       UV; MV       RDW; Stage; PLR
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Wang\           China                 MM                                                      retrospective   I-III                                             ISS                 196           65 (33-82)                                                 86/110                                             ROC                                      18.05%                        OS                 MV           RDW; Age; gender; Albumin; Lactate dehydrogenase; Creatinine
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Xu\             China                 Glioma                                                  retrospective   Low grade; High grade                             WHO 2007            168           44.1 ± 14.6                                                168/0                                              NR                                       13.20%                        PFS                UV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Yazic\          Turkey                GC                                                      retrospective   I-III                                             AJCC/\              173           61.7 ± 12                                                  62/110                                             Mean                                     16.00%                        OS                 MV           RDW; Gender; Age; Tumor diameter; Vascular invasion; PNI; Metastatic LN; PRBC; Complication; T1; PDW; MCV
  et al 2017                                                                                                                                                      UICC-7                                                                                                                                                                                                                                                 

  Zheng\          China                 Cervical cancer                                         retrospective   IA1-IIA2                                          FIGO                800           49.5 ± 10.7                                                800/0                                              ROC                                      12.70%                        OS; DFS            UV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Zhou\           China                 DLBL                                                    retrospective   I-IV                                              Ann Arbor           161           59.1±11.4                                                  70/91                                              ROC                                      14.10%                        OS; PFS            MV           
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Zhu\            China                 HCC                                                     retrospective   I-III                                             NR                  316           52.2 (22.0-80.0)                                           Training cohort 26/159; Validation cohort 20/111   ROC                                      13.25%                        OS; DFS            MV; UV       RDW; FIB-4; NLR; PLR; Liver cirrhosis; Tumor size; Tumor capsule; Tumor thrombus; TNM stage
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Życzkowski\     Poland                RCC                                                     retrospective   I-IV                                              AJCC-7              434           62.0 (54.0-69.0)                                           203/231                                            ROC                                      13.90%                        CSS                MV           RDW; Age; Gender; T stage; Distant metastases; Nephrectomy; Tumor necrosis; Grading
  et al 2017                                                                                                                                                                                                                                                                                                                                                                                                             

  Han\            China                 CRC                                                     retrospective   I-IV                                              NR                  128           NR                                                         167/73                                             ROC                                      13.45%                        OS; DFS            UV; MV       RDW; Differentiation; CA19‐9
  et al 2018                                                                                                                                                                                                                                                                                                                                                                                                             

  Ma\             China                 MM                                                      retrospective   I-III                                             ISS; DSS            78            60.7 (43-81)                                               31/47                                              ROC                                      15.50%                        OS; PFS            UV           RDW; B symptoms; IPI; ECOG PS; LDH; Stage; Bone marrow involvement; Extranodal sites of disease; Hemoglobin
  et al 2018                                                                                                                                                                                                                                                                                                                                                                                                             

  Zhang\          China                 Rectal cancer                                           retrospective   I-III                                             AJCC-7              625           NR                                                         241/384                                            ROC                                      RDW-cv 14.1%; RDW-sd 48.2fL   OS; DFS            MV           RDW; Tumor location; Tumor size; Differentiation; TNM; Vascular invasion; Perineural invasion
  et al 2018                                                                                                                                                                                                                                                                                                                                                                                                             

  Zhou\           China                 MM                                                      retrospective   I-III                                             ISS                 162           61 (40-87)                                                 75/87                                              Upper limit                              14.00%                        OS; PFS            UV           
  et al 2018                                                                                                                                                                                                                                                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** GC = gastric cancer; ESCC = esophageal squamous cell carcinoma; CRC = colorectal carcinoma; HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; RCC = renal cell cancer; UTUC = Upper tract urothelial carcinoma; MM = multiple myeloma; chronic lymphocytic leukemia = CLL; CML = Chronic Myeloid Leukemia; DLBL = diffuse large B-cell lymphomas; AJCC = The American Joint Committee on Cancer; BCLC = Barcelona Clinic Liver Cancer guidelines; UICC = International Union Against Cancer; DSS = Durie and Salmon staging system; ISS = International Staging System; OS = overall survival; PFS = progression free survival; RFS = recurrence free survival; DFS = disease free survival; event-free survival = EFS; MV = multivariate; UV = univariate; RDW-CV = red blood cell distribution width coefficient of variation; RDW-SD = red blood cell distribution width standard deviation; NR = not reported

a\. Age reported as either mean ± standard deviation or median (range), if not otherwise specified.

b\. Multiple malignancies include brain, breast, lung, upper or lower gastrointestinal tract, pancreas, kidney, prostate or gynecological system; sarcoma and hematologic malignancies (lymphoma, multiple myeloma)

c\. Studies defined cut-offs value based on previous studies.

###### 

Subgroup analyses of the associations between RDW and OS in cancer.

  Stratified analyses               No. of patients   No. of studies   Model    Pooled HR (95%CI)     P value   P~D~ value   Heterogeneity   
  --------------------------------- ----------------- ---------------- -------- --------------------- --------- ------------ --------------- ---------
  **Tumor type**                                                                                                \<0.001                      
  Hematologic malignancies          1979              10               fixed    2.046 (1.623-2.580)   \<0.001                21.2%           0.248
  MM                                748               5                fixed    1.692 (1.256-2.281)   0.001                  18.8%           0.295
  DLBCL                             881               2                fixed    3.178 (1.853-5.450)   \<0.001                0.0%            0.793
  UGI cancer                        3805              6                random   1.091 (0.925-1.286)   0.303                  73.4%           0.001
  HCC                               1510              5                random   1.430 (1.232-1.660)   \<0.001                79.9%           \<0.001
  NSCLC                             2304              4                random   1.440 (1.103-1.880)   0.007                  57.2%           0.053
  Breast cancer                     2627              3                random   2.092 (0.833-5.255)   0.116                  80.3%           0.006
  Colorectal carcinoma              843               3                fixed    1.932 (1.397-2.673)   \<0.001                0.0%            0.521
  Gliomas                           287               2                fixed    1.466 (1.129-1.904)   \<0.001                23.9%           0.252
  UTUC                              420               1\*              fixed    2.172 (1.599-2.949)   \<0.001                3.5%            0.309
  **Stage**                                                                                                     \<0.001                      
  Mix stage                         16786             33               random   1.494 (1.372-1.626)   \<0.001                80.5%           \<0.001
  Early stage                       1545              5                fixed    1.690 (1.180-2.422)   0.004                  41.0%           0.148
  Advanced Stage                    1416              6                random   1.717 (1.235-2.386)   0.001                  57.7%           0.038
  **Age**                                                                                                       \<0.001                      
  ≤60                               7979              19               random   1.590 (1.321-1.914)   \<0.001                82.6%           \<0.001
  \>60                              7992              22               random   1.515 (1.351-1.699)   \<0.001                75.7%           \<0.001
  **Gender distribution**                                                                                       \<0.001                      
  Female dominant                   5059              9                random   1.401 (1.153-1.703)   0.001                  74.9%           0.001
  Balanced                          6418              21               random   1.696 (1.441-1.997)   \<0.001                74.8%           \<0.001
  Male dominant                     5325              14               random   1.413 (1.232-1.620)   \<0.001                81.6%           \<0.001
  **Country**                                                                                                   \<0.001                      
  Eastern                           10608             28               random   1.716 (1.458-2.020)   \<0.001                79.8%           \<0.001
  Western                           8180              17               random   1.316 (1.203-1.439)   \<0.001                80.9%           \<0.001
  **Cut-off value**                                                                                             \<0.001                      
  \>15%                             3356              6                random   1.608 (1.107-2.335)   0.013                  89.5%           \<0.001
  \>14% and ≤ 15%                   7911              21               random   1.510 (1.351-1.688)   \<0.001                79.2%           \<0.001
  \>13% and ≤ 14%                   3409              11               random   1.869 (1.493-2.340)   \<0.001                57.5%           0.004
  ≤13%                              1982              5                fixed    1.534 (1.262-1.865)   \<0.001                0.0%            0.655
  **Definition of cut-off value**                                                                               \<0.001                      
  ROC curve analysis                6276              22               fixed    1.569 (1.434-1.718)   \<0.001                42.6%           0.015
  Upper limit                       3558              11               random   1.504 (1.296-1.746)   \<0.001                70.8%           0.000
  Median                            2357              3                random   1.400 (0.961-2.040)   0.080                  62.4%           0.046
  4th quartile                      2757              3                random   1.647 (1.430-1.897)   \<0.001                0.0%            0.645
  Arbitrary^\#^                     922               5                random   1.682 (1.073-2.638)   0.023                  63.2%           0.028
  **HR calculation^‡^**                                                                                         \<0.001                      
  Multivariate                      13572             28               random   1.477 (1.342-1.626)   \<0.001                83.9%           \<0.001
  Univariate                        4275              17               fixed    1.525 (1.380-1.686)   \<0.001                8.5%            0.355

**Abbreviations:** MM = Multiple Myeloma; DLBCL = Diffuse large B-cell lymphoma; UGI cancer = upper gastrointestinal tract (UGI) cancers (including esophagus cancer, gastric cancer, and small intestine cancer); HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; UTUC = upper tract urothelial carcinoma; OS = overall survival; HR = hazard ratio; CI = confidence interval; P~D~ = P for subgroup difference; P~H~ = P for heterogeneity.

\*: Cheng et al 2015 separately evaluated the survival outcome in two cohorts, which were derivation cohort and validation cohort.

\#: Definition of cut-offs value of RDW was based on previous study.

‡: HRs were extracted from multivariate cox proportional hazards models, univariate cox proportional hazards models or survival curve analysis.
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